News
EVAX
4.060
+6.84%
0.260
Evaxion Biotech reports last patient visit in one-year extension of EVX-01 trial
TipRanks · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Artivion (AORT), LB Pharmaceuticals, Inc. (LBRX)
TipRanks · 1d ago
Evaxion Completes One-Year Extension of Phase 2 Trial for AI-Designed Melanoma Vaccine EVX-01
TipRanks · 1d ago
Evaxion Announces Final Patient Visit In One-Year Extension Phase 2 Trial Of Personalized Melanoma Cancer Vaccine EVX-01
Benzinga · 1d ago
Evaxion completes phase 2 EVX-01 trial extension; three-year data due H2 2026
Reuters · 1d ago
Weekly Report: what happened at EVAX last week (0330-0403)?
Weekly Report · 2d ago
Evaxion to Unveil AI-Designed Polio and CMV Vaccine Concepts at World Vaccine Congress
TipRanks · 03/30 13:07
Evaxion to present AI-designed next-generation polio vaccine concepts at World Vaccine Congress
Reuters · 03/30 12:01
Weekly Report: what happened at EVAX last week (0323-0327)?
Weekly Report · 03/30 10:24
Weekly Report: what happened at EVAX last week (0316-0320)?
Weekly Report · 03/23 10:21
Evaxion Calls April 16, 2026 AGM to Expand Capital and Warrant Authorizations
TipRanks · 03/19 13:31
Evaxion Biotech Sets April 16, 2026 Date for Annual General Meeting
TipRanks · 03/19 13:31
Evaxion shareholders to vote on board authority for DKK 73.5 million convertible loan notes
Reuters · 03/19 13:01
Evaxion A/S CFO Thomas Frederik Schmidt files initial beneficial ownership statement
Reuters · 03/19 01:11
Evaxion A/S files initial beneficial ownership statement for Chief AI Officer Andreas Holm Mattsson
Reuters · 03/19 01:09
Evaxion A/S files Form 3 initial beneficial ownership statement for Chief Scientific Officer Birgitte Rono
Reuters · 03/19 01:08
Evaxion A/S Director Lars Holtug Files Initial Statement of Beneficial Ownership
Reuters · 03/19 01:07
Evaxion A/S CEO Helen Katrina Tayton-Martin files initial beneficial ownership statement
Reuters · 03/19 01:06
Evaxion to Present New AI-Driven Cancer Vaccine Data at AACR 2026
TipRanks · 03/17 20:57
Evaxion to present two abstracts and attend AACR Oncology Industry Partnering event
Reuters · 03/17 20:30
More
Webull provides a variety of real-time EVAX stock news. You can receive the latest news about Evaxion AS through multiple platforms. This information may help you make smarter investment decisions.
About EVAX
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.